9 Meters Biopharma, Inc. NMTR
0.07 0.00 (+0.00%)
At closeJul 25, 2023, 4:00 PM EDT
0.0715 Day range 0.1127
52-week range unavailable
Analyst view
Consensus: buy
Buy
Price target (mean) 10.38 +14276.7% upside
Now 0.0722
- Target (low)
- 0.75
- Target (mean)
- 10.38
- Target (high)
- 20.00
Ratings (-1m) 6 3 buy · 3 hold · 0 sell
- Strong buy2
- Buy1
- Hold3
- Sell0
- Strong sell0
Recommendation trend
- 1 month ago 6
- 2 months ago 6
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.57 | -1.06 – -0.41 | -0.80 | +28.8% | 0 | 0.0% | 5 |
| Next quarter | -0.40 | -1.06 – 0.34 | -0.72 | +44.4% | 0 | 0.0% | 5 |
| Current year | -2.18 | -4.20 – -1.07 | -3.38 | +35.5% | 2.50M | 0.0% | 5 |
| Next year | -2.53 | -4.50 – -1.23 | -2.18 | -16.1% | 0 | 0.0% | 4 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 1, 2023 | Citigroup | Maintained | Neutral | Neutral |
| May 18, 2023 | Citigroup | Maintained | Neutral | Neutral |
| Mar 20, 2023 | Truist Securities | Downgrade | Buy | Hold |
| Feb 13, 2023 | Citigroup | Initiated | — | Neutral |
| Nov 10, 2022 | BMO Capital | Maintained | — | Outperform |
| Sep 27, 2022 | Oppenheimer | Maintained | — | Outperform |
| Jul 1, 2022 | Maxim Group | Downgrade | Buy | Hold |
| Jun 22, 2022 | Truist Securities | Maintained | — | Buy |
| Jun 22, 2022 | BMO Capital | Maintained | — | Outperform |
| Jul 8, 2021 | BMO Capital | Initiated | — | Outperform |
| Jun 4, 2021 | Citigroup | Initiated | — | Buy |
| Jan 29, 2021 | Oppenheimer | Initiated | — | Outperform |
| Sep 23, 2020 | William Blair | Initiated | — | Outperform |
| Aug 18, 2020 | Brookline Capital | Initiated | — | Buy |